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While the morphology and function of cells of the exocrine and endocrine pancreas have
been studied over several centuries, one important cell type in the gland, the pancreatic
stellate cell (PSC), had remained undiscovered until as recently as 20 years ago. Even
after its first description in 1982, it was to be another 16 years before its biology could
begin to be studied, because it was only in 1998 that methods were developed to
isolate and culture PSCs from rodent and human pancreas. PSCs are now known to
play a critical role in pancreatic fibrosis, a consistent histological feature of two major
diseases of the pancreas—chronic pancreatitis and pancreatic cancer. In health, PSCs
maintain normal tissue architecture via regulation of the synthesis and degradation of
extracellular matrix (ECM) proteins. Recent studies have also implied other functions for
PSCs as progenitor cells, immune cells or intermediaries in exocrine pancreatic secretion
in humans. During pancreatic injury, PSCs transform from their quiescent phase into an
activated, myofibroblast-like phenotype that secretes excessive amounts of ECM proteins
leading to the fibrosis of chronic pancreatitis and pancreatic cancer. An ever increasing
number of factors that stimulate and/or inhibit PSC activation via paracrine and autocrine
pathways are being identified and characterized. It is also now established that PSCs
interact closely with pancreatic cancer cells to facilitate cancer progression. Based on
these findings, several therapeutic strategies have been examined in experimental models
of chronic pancreatitis as well as pancreatic cancer, in a bid to inhibit/retard PSC activation
and thereby alleviate chronic pancreatitis or reduce tumor growth in pancreatic cancer.
The challenge that remains is to translate these pre-clinical developments into clinically
applicable treatments for patients with chronic pancreatitis and pancreatic cancer.
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INTRODUCTION
“I will love the light for it shows me the way, yet I will endure the
darkness because it shows me the stars.” Og Mandino (American
Essayist and Psychologist, 1923–1996).
Although both exocrine and endocrine functions of the pan-
creas and the cell types relevant to these functions (acinar cells,
ductal cells, and cells of the islets of Langerhans) have been exten-
sively studied since the pancreas was first described byHerophelus
(335–280 BC) (Howard and Hess, 2002), one major cell type
remained in the dark until as recently as 20 years ago. This cell
type, the pancreatic stellate cell (PSC, so called because of its
star-like appearance in situ) was first reported by Watari (Watari
et al., 1982) in 1982 using electron microscopy of rodent and
human pancreas. Watari likened these cells to hepatic stellate
cells, which are well established as the key effector cells in liver
fibrosis. However, there was little further effort in the field to
characterize PSCs or to determine whether they played a similar
fibrogenic role in the pancreas as their hepatic counterparts. This
Abbreviations: PSCs, pancreatic stellate cells; PDGF, platelet derived growth fac-
tor; TGFb, transforming growth factor beta; HGF, hepatocyte growth factor; VEGF:
vascular endothelial growth factor; IL, interleukin; NFkB, nuclear factor kappa
B; AP-1: activator protein 1; αSMA, alpha smooth muscle actin; TLR, toll like
receptor.
possibly reflected a general disinterest at the time in the mecha-
nisms of pancreatic fibrosis which, despite being a predominant
histological feature of two major pancreatic diseases (chronic
pancreatitis and pancreatic cancer), was mostly considered to be
an epiphenomenon of chronic injury.
It was to be another 16 years sinceWatari’s initial report before
methods were developed to isolate and culture PSCs, which finally
provided researchers with a tool to study the mechanisms respon-
sible for pancreatic fibrosis. In general, fibrosis is defined as the
excessive accumulation of extracellular matrix (ECM) proteins
(particularly fibrillar collagens) as a result of a loss of the nor-
mal balance between the deposition and the degradation of ECM.
The concept of fibrosis as an inert, reactive tissue has changed sig-
nificantly in recent times. Indeed, it is now well recognized that
fibrogenesis in the pancreas is an active, dynamic process that
may be reversible, at least in the early stages. Importantly, there
is unequivocal evidence to indicate that PSCs play a central role
in pancreatic fibrogenesis (Apte et al., 2011).
THE HISTORY OF STELLATE CELLS
In contrast to the pancreas, where the fibrogenic process has only
received attention in recent years, the mechanisms of fibrosis in
the liver have been well studied over several decades. Stellate cells
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were identified in the liver more than 130 years ago by the famous
pathologist Karl Wilhelm von Kupffer. In a letter written in 1876
to his colleague Heinrich von Waldeyer, Kupffer described star
shaped cells (“sternzellen”) stained with gold chloride in peris-
inusoidal spaces in the liver. However, Kupffer was unsure at
the time as to whether these cells were different from resident
liver macrophages, and this resulted in considerable confusion
in the field for several decades. Almost 75 years after Kupffer’s
first description of “sternzellen,” Ito (Ito, 1951) reported the pres-
ence of lipid-containing cells in a perisinusoidal location in the
liver which he termed as Ito cells. Finally in 1971, Wake and
colleagues (Wake et al., 1987), used multiple techniques (gold
chloride staining, lipid staining and electron microscopy) which
clearly demonstrated that vitamin A storing hepatic stellate cells
were the same as the Ito cells and also the same as the sternzellen
initially reported by Kupffer, but were distinctly different from
liver macrophages (also known as Kupffer cells). Rapid progress
was made in the field following this clarification, with detailed
characterization of the biology and functions of hepatic stellate
cells, from the first report of the possible role of HSCs in colla-
gen synthesis by Kent and colleagues (Kent et al., 1976) in 1976,
to the current time where HSCs are established as not only cen-
tral to the production of ECM proteins but also as serving several
other functions including roles in liver development and regen-
eration, retinoid metabolism and immunomodulation (Lee and
Friedman, 2011).
As noted earlier, the pancreatic counterparts of HSCs were first
described by Watari in 1982, (more than a hundred years after
Kupffer’s initial reports in the liver). Watari examined the pan-
creas of vitamin A loaded mice by fluorescence microscopy and
electron microscopy and described the presence of cells exhibiting
a rapidly fading blue-green fluorescence characteristic of vitamin
A in the periacinar areas of the pancreas (Watari et al., 1982). In
1990, a similar (albeit sparsely distributed) vitamin A autofluo-
rescence was reported in normal pancreatic sections from rats
and humans by Ikejiri (Ikejiri, 1990). A few years later, in 1998,
two seminal papers were published describing the isolation and
culture of PSCs from rat and human pancreas (Apte et al., 1998;
Bachem et al., 1998). These methods proved to be a major break-
through because they finally provided an invaluable in vitro tool
for researchers to characterize the biology of PSCs in health and
disease.
PANCREATIC STELLATE CELLS
PSCs are located adjacent to the basolateral aspects of pancreatic
acinar cells and have also been identified around small pancre-
atic ducts and blood vessels (Figure 1) (Watari et al., 1982; Ikejiri,
1990; Apte et al., 1998). They comprise approximately 4–7% of
the total cell mass in the gland (Apte et al., 1998; Bachem et al.,
1998). In the healthy pancreas, PSCs exhibit abundant, vitamin
A containing lipid droplets in their cytoplasm and are in their
quiescent (non-activated) state. They can be differentiated from
fibroblasts due to their expression of selective markers such as
desmin, glial fibrillary acidic protein (GFAP), vimentin and nestin
(intermediate filament proteins) and neuroectodermal markers
such as nerve growth factor (NGF) and neural cell adhesion
molecule (NCAM). On electron microscopic examination, PSCs
FIGURE 1 | Pancreatic stellate cells in rat pancreas stained for the
selective marker desmin. The left panel shows a representative
photomicrograph of normal rat pancreas immunostained for desmin. The
right panel depicts the corresponding line diagram. Desmin positive PSCs
with long cytoplasmic projections are located at the basolateral aspect of
acinar cells (A). Reprinted with permission from BMJ Group.
reveal a prominent rough endoplasmic reticulum, collagen fibrils
and vacuoles (lipid droplets) surrounding a central nucleus.
CHARACTERISTICSOF QUIESCENT (NON-ACTIVATED) PSCs
These have been essentially determined using PSCs isolated from
normal rat and human pancreas. Taking their cues from the
method used to isolate HSCs, Apte et al. (1998) developed a
technique to isolate PSCs based on the knowledge that in the
normal pancreas, PSCs contain abundant lipid droplets in their
cytoplasm which decreases cell density. Consequently, when a
suspension of pancreatic cells is centrifuged through a density
gradient, PSCs can be readily separated from other pancreatic
cells (Apte et al., 1998). When placed in plastic culture wells, qui-
escent PSCs exhibit a flattened polygonal shape with prominent
lipid droplets in the cytoplasm surrounding the central nucleus
(Figure 2). Exposure of the cells to UV light at 328 nm elicits a
transient blue-green fluorescence typical of vitamin A. After being
in culture for a period of about 48 h, these quiescent PSCs become
activated, a process that is inevitably associated with a loss of
the cytoplasmic vitamin A droplets and a transformation of cell
shape to a myofibroblast like phenotype that now expresses the
cytoskeletal protein α smooth muscle actin (αSMA).
Although the presence of vitamin A containing lipid droplets
in the cytoplasm is a specific marker of quiescent stellate cells,
little is known about the mechanisms mediating their accumula-
tion. Two recent studies by the same group of researchers have
endeavoured to shed some light on this process. Kim and col-
leagues (Kim et al., 2009, 2010) have postulated that albumin (a
protein that is endogenously expressed in PSCs and is co-localized
with vitamin A in the lipid droplets) may play a role in lipid
droplets formation. When the authors transfected activated PSCs
(which had lost their lipid droplets) with expression plasmids for
albumin, the cells exhibited a re-accumulation of lipid droplets
that contained vitamin A (as confirmed by UV exposure). This
was associated with increased resistance of the cells to the activat-
ing effects of the well known profibrogenic factor transforming
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FIGURE 2 | PSCs in early culture. The cells exhibit a flattened polygonal
shape with abundant lipid droplets (containing vitamin A) in the cytoplasm,
surrounding the central nucleus. Reprinted with permission from BMJ
Group.
growth factor beta (TGFβ). The authors have further shown that
albumin is a downstream effector of the nuclear receptor perox-
isome proliferator activated receptor γ (PPARγ) which is known
to inhibit PSC activation (vide infra). While these studies pro-
vide interesting insights into the formation of vitamin A lipid
droplets in PSCs, the mechanisms mediating their loss during
PSC activation remain to be elucidated.
PSCs have the capacity to proliferate, to migrate and to syn-
thesize and secrete proteins ECM proteins. Each of these func-
tions is significantly stimulated during the activation process
(see below). In addition to the production of ECM proteins,
PSCs also produce matrix degrading enzymes (matrix metallo-
proteinases, MMPs) and their inhibitors (TIMPs, tissue inhibitor
of metalloproteinases) (Phillips et al., 2003), suggesting that in
health the cells may be responsible for the maintenance of nor-
mal ECM turnover in the pancreas. However, during pancreatic
injury, when PSCs are activated, the balance between ECM pro-
duction and ECM degradation is severely disturbed, leading to
excessive ECM synthesis and eventually to the development of
pathological fibrosis.With the availability of improved techniques
for proteomic analyses based on mass spectrometry, three recent
studies have assessed the differences in the proteomes of non-
activated versus activated mouse (Paulo et al., 2011a), rat (Paulo
et al., 2011b) and human (Wehr et al., 2011) PSCs. A detailed
description of all differences is beyond the scope of this article,
but it is interesting to note that numerous proteins were found
to be differentially expressed in the two states, with proteins in
the activated states being those related to the cell cytoskeleton,
cell metabolism, motility, growth and invasion. (Table 1 sum-
marizes the different characteristics of quiescent and activated
PSCs).
Table 1 | Characteristics of quiescent and activated PSC phenotypes.
Quiescent PSCs Activated PSCs
Vitamin A lipid
droplets
Present Absent
α Smooth muscle
actin
Absent Present
Proliferation Limited Increased
Migration Limited Increased
Extracellular
matrix production
Limited Increased
Matrix metallo-
proteinases
(MMPs) and
tissue inhibitors
of matrix
proteinases
(TIMPs)
Complement of
MMPs and TIMPs to
maintain normal
ECM turnover
Change in types of
MMPs and TIMPs to
facilitate ECM
deposition
Production of
cytokines
Limited Increased (PDGF,
TGFβ, CTGF, IL1, IL6,
IL15)
Capacity for
phagocytosis
Absent Present
Proteomic
analyses
Basal protein
expression
Differential
expression of
proteins related to
the cell cytoskeleton,
cell metabolism,
motility, growth and
invasion
While the initial focus of PSC related research was on under-
standing the role of activated PSCs in fibrosis (discussed in
detail later), more recent efforts have been directed toward other
non-fibrogenic functions of quiescent cells. Accumulating evi-
dence suggests that PSCs may function as (1) progenitor cells;
(2) immune cells or (3) intermediary cells in cholecystokinin
(CCK)-induced pancreatic digestive enzyme (exocrine) secretion.
With regard to their possible progenitor function, Mato et al.
(2009) isolated and expanded pancreatic cells from lactating rats
using mitoxantrone (a drug that acts through multidrug trans-
porter systems) selection. They have reported that the surviv-
ing, mitoxantrone-resistant cells showed a PSC-like morphology
(fibroblast-like with vitamin A lipid droplets), expressed the stem
cell marker ABCG2 transporter (ATP binding cassette G2 trans-
porter) and were able to secrete insulin after cell differentiation.
However, whether such a selected “drug resistant” population is
representative of normal PSCs remains to be examined. In order
to determine whether the cells are true progenitor cells, additional
work is needed to assess whether PSCs express other stem cell
markers and can transform (under physiological conditions) into
other cell types.
In terms of an immune function, Shimizu et al. (2005) were the
first to observe that PSCs could internalize necrotic acinar cells
and apoptotic neutrophils, but this was associated with necrotic
cell death of the PSCs themselves. These in vitro observations
were supported by the authors’ in vivo work using a mouse model
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of bile-duct ligation induced acute pancreatitis and a model of
spontaneous chronic pancreatitis (WBN/Kob rats) in which they
found that PSCs engulfed damaged parenchymal cells. Thus,
the authors speculated that PSCs may exhibit a locally protec-
tive “innate” immune function to inhibit disease progression in
early pancreatic injury. The role of PSCs in innate immunity is
supported by the fact that the cells express Toll like receptors
(TLR2, 3, 4, 5 and 9) which recognize foreign pathogen-associated
molecular patterns (PAMPs) (Vonlaufen et al., 2007b; Masamune
et al., 2008a; Nakamura et al., 2011). More recently, Shimizu
and colleagues (2012) investigated whether PSCs may also have
an “acquired” immune function by acting as antigen presenting
cells. However, they found that rat PSCs did not express any anti-
gen presenting cell markers such as MHC class II molecules or
HLA-DR molecules. This finding differs from reports with HSCs
which have been shown to process lipid antigens and present
them to natural killer cells via CD1d. HSCs have also been shown
to process protein antigens and present them to CD4 and CD8
positive T cells (Unanue, 2007; Winau et al., 2007). It is possible
that the antigen-presenting capacity in HSCs develops because
of the consistent exposure of the liver to foreign antigens from
the gastrointestinal tract via the portal vein, whereas the pancreas
(and PSCs) in comparison would be less likely to be exposed to
the same load of exogenous antigens.
The question as to whether PSCs may play an intermedi-
ary role in CCK-induced digestive enzyme secretion arose from
the known proximity of the PSCs to acinar cells in situ and the
debate in the literature about the presence of functional CCK
receptors on human acinar cells (in contrast to rat acinar cells
where CCK receptors have been well identified). Two recent
studies have convincingly demonstrated the presence of CCK
receptors 1 and 2 on human PSCs (Berna et al., 2010; Phillips
et al., 2010). Furthermore, the study by Phillips et al. (2010)
has shown that PSCs respond to CCK by producing the neuro-
transmitter acetylcholine which can act on muscarinic receptors
on acinar cells. Using a co-culture system of PSCs and acinar
cells, the authors have also demonstrated an increase in amy-
lase output by acinar cells in the presence of PSCs, which could
be inhibited by the muscarinic receptor blocker atropine. These
findings indicate that in humans, PSCs may play a significant
intermediary role in regulating CCK-induced exocrine pancreatic
secretion.
CENTRAL ROLE OF ACTIVATED PSCs IN PANCREATIC
FIBROSIS
In vitro and in vivo studies over the past 14 years (ever since the
first descriptions of methods to isolate PSCs) have now convinc-
ingly demonstrated that when activated during pancreatic injury,
PSCs play a critical role in the pathogenesis of pancreatic fibrosis.
ACTIVATION OF PSCs – In vitro STUDIES
As noted earlier, transformation of PSCs from their quiescent
to an activated state is a key event in fibrogenesis, result-
ing in excessive synthesis and deposition of ECM proteins.
Specific molecules/factors and cellular pathways that mediate
PSC activation were initially identified mostly by using cultured
PSCs in vitro. The selection of putative activating factors for
examination was based upon the knowledge that during the pro-
cess of tissue injury, PSCs are likely to be exposed to factors
such as: (1) alcohol and its metabolites acetaldehyde and fatty
acid ethyl esters (FAEEs) [in view of the well known role of
alcohol in pancreatitis (Apte et al., 2011)]; (2) endotoxin [given
the known association of alcohol abuse and endotoxinaemia
(Parlesak, 2005) and the correlation of circulating endotoxin lev-
els with severity of pancreatitis (Windsor et al., 1993; Ammori
et al., 1999)]; (3) growth factors and cytokines - transforming
growth factor β (TGFβ), platelet derived growth factor (PDGF),
tumour necrosis factor α (TNFα) and interleukins (IL), all of
which are upregulated during pancreatic damage (Vonlaufen
et al., 2007b); (4) oxidant stress (known to occur during both
acute and chronic pancreatitis) (Uden et al., 1990; Casini et al.,
2000); and (5) increased pancreatic pressure due to the “com-
partment syndrome” of chronic pancreatitis (Jalleh et al., 1991).
To this list of activating factors have been added several others in
recent years, on the basis of their overexpression in and/or asso-
ciation with chronic pancreatitis. These include hyperglycaemia
[given that diabetes is a known complication of chronic pan-
creatitis (Nomiyama et al., 2007)], the endothelial cell derived
vasoconstrictor endothelin-1 (Jonitz et al., 2009), cyclooxyge-
nase 2 (COX-2, the inducible form of the rate limiting enzyme
that converts arachidonic acid to prostaglandin) (Aoki et al.,
2007), galectin-1 (a beta-galactoside binding lectin) (Masamune
et al., 2006a) and the haemostatic protein fibrinogen (Masamune
et al., 2009).
PSC activation in response to the above factors has gener-
ally been assessed using one or more of a number of “activa-
tion” parameters such as cell proliferation, αSMA expression,
ECM protein synthesis, matrix degradation via the produc-
tion of matrix metalloproteinases, loss of vitamin A stores, cell
migration, cytokine release and contractility. Alcohol (ethanol)
itself directly activates PSCs most likely due to the oxidative
metabolism of ethanol to acetaldehyde via the enzyme alcohol
dehydrogenase (ADH, known to be active in PSCs), and the sub-
sequent generation of oxidant stress within the cell (Apte et al.,
2000). Interestingly, ethanol upregulates PDGF-induced NADPH
oxidase activity within PSCs (Hu et al., 2007), supporting the con-
cept that reactive oxygen species (ROS) generated within PSCs
play a role in PSC activation. It is noteworthy that ethanol can
activate PSCs from their quiescent state and does not require the
cells to be pre-activated to exert its stimulatory effects (Apte et al.,
2000), suggesting that in vivo, PSC activation may occur early
during chronic alcohol intake even in the absence of necroin-
flammation. This activation may then be perpetuated further
during ethanol-induced necroinflammatory episodes leading to
the development of fibrosis. Ethanol also inhibits PSC apoptosis
(as assessed by the standard apoptosis indices Annexin V staining,
TUNEL staining and caspase 3 and 9 activities) thereby facilitat-
ing cell survival (Vonlaufen et al., 2011). Furthermore, ethanol
enhances the inhibitory effect of endotoxin lipopolysaccharide
(LPS) on PSC apoptosis, suggesting that these two factors may
exert synergistic effects on PSCs which promote cell activation
and survival, thereby promoting pancreatic fibrosis. In contrast
to the effects of the oxidative ethanol metabolite acetaldehyde on
PSCs, the non-oxidative ethanol metabolites (FAEEs) have not
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yet been reported to activate PSCs. However, one of the FAEEs,
palmitic acid ethyl ester (PAEE), has been shown to stimulate
specific signaling molecules within PSCs (see below) (Masamune
et al., 2004).
With regard to cytokines, it is now well established that
(a) PDGF is a potent proliferative and chemotactic factor for
PSCs; (b) TGFβ and its downstream effector connective tis-
sue growth factor (CTGF) stimulate the synthesis and secretion
of ECM proteins (collagen, fibronectin, and laminin) by PSCs;
TGFβ also induces matrix metalloproteinase 2 (MMP2) produc-
tion by the cells [it is postulated that degradation of normal
basement membrane collagen by MMP2, facilitates the deposi-
tion of abnormal (fibrillar) collagen, thereby promoting fibrosis];
(c) the proinflammatory cytokines TNFα, monocyte chemotactic
protein (MCP-1) and IL1, IL6 and IL13 stimulate proliferation,
αSMA expression and/or collagen synthesis in PSCs (Apte et al.,
1999; Schneider et al., 2001; Mews et al., 2002; Michalski et al.,
2007).
It is important to note that, in addition to responding to exoge-
nous cytokines via paracrine pathways, PSCs themselves produce
inflammatory mediators including TGFβ, CTGF, MCP-1, IL1,
IL8, IL15 and RANTES (Regulated on Activation Normal T Cell
Expressed and Secreted), all of which are capable of activating the
cells via autocrine pathways (Andoh et al., 2000; Shek et al., 2002).
The production of these endogenous cytokines can be stimulated
by exogenous compounds such as ethanol, acetaldehyde, TGFβ
and CTGF (Mews et al., 2002; Karger et al., 2008) and also by
autocrine loops between certain cytokines in PSCs. For exam-
ple, Aoki et al. (2006) have shown that IL-1β and IL6 produced
by PSCs can each stimulate the autocrine secretion of TGFβ by
the cells, and vice versa. In contrast IL13 (a Th2 lymphokine)
suppresses TGFβ secretion by rat PSCs, although it induces PSC
proliferation (Shinozaki et al., 2010). However, the relevance to
human pancreatic fibrosis of the IL13 induced suppression of
TGFβ secretion by rat PSCs is difficult to assess since the IL13
receptor system has not been detected in human pancreatitis
specimens. Nonetheless, the ability of PSCs to be activated via
autocrine pathways suggests that once activated, PSCs are capa-
ble of being in a perpetually activated state even in the absence
of the initial trigger factors (Figure 3). This phenomenon may
represent one of the mechanisms responsible for progression of
chronic pancreatitis despite the cessation of the initial insult, for
example alcohol and/or acute flare.
Oxidant stress (produced by exposure of cells to a pro-oxidant
complex such as iron sulphate/ascorbic acid or hydrogen per-
oxide) activates PSCs and this activation is prevented by the
antioxidant α-tocopherol (vitamin E) (Apte et al., 2000; Kikuta
et al., 2004, 2006). PSCs have also been shown to generate ROS
within the cell (Apte et al., 2000). Interestingly, (Masamune et al.,
2008b) have demonstrated that PSCs express NADPHoxidase (an
enzyme that is primarily found in phagocytic cells such as neu-
trophils and macrophages) to generate intracellular ROS, which,
in turn, mediate activation of PSCs.
As noted earlier, pancreatic tissue pressure is elevated in
chronic pancreatitis compared to normal pancreas. Asaumi et al.
(2007) have reported activation of PSCs upon exposure to high
pressure conditions (80mmHg) produced using helium gas and a
FIGURE 3 | Perpetuation of PSC activation. A diagrammatic
representation of the postulated pathway for a perpetually activated state
for PSCs. Pancreatic stellate cells are activated via paracrine pathways by
exogenous factors such as cytokines, oxidant stress, ethanol and its
metabolites. Activated PSCs synthesize and secrete endogenous cytokines
which influence PSC function via autocrine pathways. It is possible that this
autocrine loop in activated PSCs perpetuates the activated state of the cell,
even in the absence if the initial trigger factors, leading to excessive ECM
production and eventually causing pancreatic fibrosis.
sealed pressure loading apparatus into which culture flasks bear-
ing PSCs were placed. This activating effect was prevented by
anti-oxidants such as N-acetyl cysteine (NAC) and epigallocat-
echin gallate (a green tea polyphenol), suggesting that it was
mediated by intracellular oxidant stress.
Other factors that have recently been reported to induce
PSC activation (as assessed by proliferation, migration, collagen
production, αSMA expression or cytokine expression) include
hyperglycaemia, endothelin 1, COX-2, galectin 1 and fibrinogen.
SIGNALING PATHWAYS IN PSCs
Having established the functional responses of PSCs to exoge-
nous and endogenous factors, the logical next step for researchers
in the field was to identify the intracellular signaling pathways
mediating these responses, with the ultimate aim of developing
approaches to target specific signalingmolecules so as to interrupt
PSC activation and inhibit abnormal fibrogenesis.
The activating effects of ethanol, acetaldehyde and oxidant
stress on PSCs are mediated by activation of the mitogen acti-
vated protein kinase (MAPK) pathway (extracellular signal reg-
ulated kinase (ERK1/2), p38 kinase and c-jun amino terminal
kinase (JNK), as well as the nuclear transcription factor AP-1
(Gukovskaya et al., 2002; McCarroll et al., 2003a,b). The non-
oxidative metabolite of ethanol, PAEE also activates the same
pathways in human PSCs (Masamune et al., 2004). Ethanol and
acetaldehyde also activate two signaling molecules upstream of
the MAPK cascade, phosphatidylinositol 3 kinase (PI3K) and
protein kinase C (PKC) (McCarroll et al., 2003a,b). Given the syn-
ergistic effects of ethanol and endotoxin on PSCs in vitro (noted
above), the LPS signaling pathway has recently been examined in
PSCs. The cells express the LPS receptor TLR4 (toll like receptor
4) as well as the adapter molecules CD14 and MD2 (Vonlaufen
et al., 2007b). Interestingly, TLR4 expression is upregulated in
PSCs upon exposure to LPS (Vonlaufen et al., 2007b). PSCs are
also known express other toll-like receptors, TLR2, 3 and 5 and
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exposure of the cells to relevant TLR ligands activates the tran-
scription factor NFκB (Masamune et al., 2008a). This finding is of
interest because NFκB can induce anti-apoptotic proteins such as
IAPs (inhibitor of apoptosis proteins) (Bhanot and Moller, 2009)
and may provide an explanation for the LPS-induced inhibition
of PSC apoptosis observed in vitro.
PDGF-induced PSC proliferation is mediated by ERK and
JAK/STAT (Janus activated kinases/Signal induced activation of
transcription) (Jaster et al., 2002; Masamune and Shimosegawa,
2009), while PDGF-induced migration is regulated by the PI3K
pathway (McCarroll et al., 2004). There is significant cross-talk
between PI3K and ERK in PSCs, so that modulation of one path-
way is often associated with a change in the function of the
other (McCarroll et al., 2004). Another signaling molecule which
influences PSC migration is Indian hedgehog (IHH) (Shinozaki
et al., 2008), a peptide belonging to the hedgehog protein fam-
ily that is active in pancreas development, patterning and dif-
ferentiation. PSCs express smoothened (Smo) and patched-1
(Ptch1) proteins which are essential components of the hedge-
hog receptor system. IHH – receptor binding leads to relocation
of the transcriptional factor Gli-1 to the nucleus and results in
chemotactic as well as chemokinetic migration of PSCs. This
is associated with localization of membrane type I – matrix
metalloproteinase (MT1-MMP) to the surface of PSCs, where
it is thought to aid basement membrane degradation so as to
facilitate cell movement. The profibrogenic growth factor TGFβ
exerts its effect on PSCs via the intracellular signaling mediators
SMAD2 and 3 (Ohnishi et al., 2004). TGFβ also exerts autocrine
effect on PSCs whereby it induces its own mRNA expression;
this process is regulated by the ERK pathway (Ohnishi et al.,
2004).
The well-established association of PSC activation with the
expression of the cytoskeletal protein αSMA, has prompted stud-
ies on the regulation of the actin cytoskeleton and PSC morphol-
ogy. The small GTP protein Rho and its downstream effector
Rho kinase regulate the actin cytoskeleton, stress fibre formation
and alteration of cell shape during the PSC activation process
(Masamune and Shimosegawa, 2009).
Intracellular calcium signaling, which is closely linked to the
pathways mentioned above is modulated in PSCs in response to
the binding of growth factors and cytokines to relevant recep-
tors on the cell surface (Masamune and Shimosegawa, 2009).
PSCs also respond to the extracellular nucleotides purines and
pyrimidines (known to be involved in cell-cell communication of
inflammatory signals after cell injury) via P2X and P2Y recep-
tors (Hennigs et al., 2011). Activation of P2 receptors elicits
robust intracellular Ca signaling known to mediate the fibrogenic
function of activated PSCs (Hennigs et al., 2011).
Most recently, attention has turned toward microRNAs, the
small non-coding RNAs that are implicated in many biological
processes including cell differentiation, proliferation, apoptosis
and tumorigenesis. Shen et al. (2012) have reported that miR-15b
and miR-16 modulate rat PSC apoptosis by targeting the anti-
apoptotic factor Bcl-2.
While the above discussion focuses on PSC activation path-
ways, factors and signaling molecules that inhibit PSC activation
have also been examined in recent times. In this regard, it is now
known that inhibition of MAPK (ERK, JNK and p38 kinase) sig-
naling mediates the induction of quiescence of PSCs in response
to retinol and its metabolites ATRA and 9-cisRA (McCarroll et al.,
2003a,b). Curcumin, a polyphenol compound found in turmeric,
decreases PDGF-induced PSC proliferation via inhibition of the
ERK pathway; it also inhibits cytokine-induced PSC activation
by inhibiting the MAPK pathway and by preventing activation
of the transcription factor AP-1 (Masamune et al., 2006b). The
peroxisome proliferator-activated receptor γ (PPAR γ, a ligand-
activated transcription factor which controls cellular growth and
differentiation) mediates the inhibitory effect of its ligand trogli-
tazone on PDGF-induced and culture-induced activation of PSCs
(Masamune et al., 2002; Shimizu et al., 2004).
PSCs IN CHRONIC PANCREATITIS
The role of PSCs in chronic pancreatitis has been assessed pre-
dominantly via ex vivo studies using pancreatic sections from
patients with chronic pancreatitis and in vivo studies using animal
models of chronic pancreatitis.
HUMAN STUDIES
Human chronic pancreatitis sections have mainly been examined
using standard histological stains (H and E, Masson’s trichrome
for connective tissue and Sirius Red for collagen) and using
immunohistochemistry for the presence of specific proteins.
These studies have clearly established that in the fibrotic pan-
creas, areas that stain positive for collagen also stain for alpha
smooth muscle actin indicating the presence of activated PSCs
(Figure 4). Moreover, using dual immunostaining for αSMA, it
has been established that it is predominantly the activated PSCs
that produce the collagen in the fibrotic areas (Haber et al., 1999).
The expression of growth factors known to activate PSCs is also
increased in chronic pancreatitis. Pancreatic acinar cells adjacent
to areas of fibrosis exhibit strong staining for TGFβ, while such
staining is absent in acinar cells remote from bands of fibrosis
(Haber et al., 1999), suggesting that TGFβ secreted by pancreatic
FIGURE 4 | Dual staining of a human chronic pancreatitis section
immunostained for the PSC activation marker α smooth muscle actin
(αSMA) and for collagen using Sirius Red. The brown staining for αSMA
is co-localized with the red staining for collagen indicating the presence of
activated PSCs in fibrotic areas of the pancreas. Reprinted with permission
from Elsevier.
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acinar cells may have a paracrine effect on PSCs, leading to
increased collagen synthesis by the cells. TGFβ staining is also evi-
dent in spindle shaped cells in the fibrotic bands. The expression
of NGF, one of the stellate cell selective markers) is also increased
in human chronic pancreatitis (Friess et al., 1999). Since NGF is
expressed by neuronal cells as well as PSCs, it is possible that pro-
liferating PSCs in fibrotic areas may contribute to the observed
increase in NGF staining in this disease. Expression of the recep-
tor for PDGF is also increased (at both mRNA and protein levels)
in areas of fibrosis in chronic pancreatitis (Haber et al., 1999).
Given that PDGF is a potent mitogenic and chemotactic factor
for PSCs, increased PDGF receptor expression on the cells may be
one of the mechanisms responsible for the increased numbers of
PSCs observed in fibrotic areas.
Interestingly, there is evidence of increased oxidant stress in
fibrotic areas of chronic pancreatitis as indicated by positive stain-
ing for 4-hydroxynonenal (4HNE, a lipid peroxidation product)
(Casini et al., 2000). This finding is highly relevant because PSCs
are known to be activated in response to oxidant stress (as noted
earlier).
ANIMAL MODELS
The human studies described above were important in terms
of confirming the association of activated PSCs with pancreatic
fibrosis in chronic pancreatitis. However, being cross-sectional
studies, they did not allow examination of chronological events
in the development of pancreatic fibrosis. This limitation was
overcome by studies with animal models (predominantly rodent
models) of pancreatic fibrosis. Fibrosis has been produced in
rodents via various approaches. Rat models described in the liter-
ature include: (1) trinitrobenzene sulfonic acid (TNBS) injection
into the pancreatic duct (Haber et al., 1999); (2) intravenous
injection of an organotin compound dubutyltin chloride (DBTC)
(Emmrich et al., 2000); (3) spontaneous chronic pancreatitis in
WBN/Kob rats (Ohashi et al., 1990); (4) severe hyperstimula-
tion obstructive pancreatitis (SHOP), involving intraperitoneal
(IP) injections of supramaximal doses of caerulein (a synthetic
analogue of CCK, a major pancreatic secretagogue) + bile-
pancreatic duct ligation (Murayama et al., 1999); (5) repeated
IP injections of a superoxide dismutase inhibitor (Matsumura
et al., 2001); (6) intragastric high dose alcohol administration
+ repeated caerulein injections (Tsukamoto et al., 1988; Uesugi
et al., 2004); (7) chronic alcohol administration (liquid diet) with
repeated cyclosporin and caerulein injections (Gukovsky et al.,
2008) and (8) chronic alcohol administration with repeated endo-
toxin LPS, injections (Vonlaufen et al., 2007b). Mouse models
of pancreatic fibrosis include: (i) transgenic mice overexpress-
ing TGFβ or the EGF receptor ligand heparin binding epider-
mal growth factor-like growth factor (HB-EGF) (Blaine et al.,
2009); (ii) repetitive pancreatic injury induced by repeated injec-
tions of supramaximal caerulein (Neuschwander-Tetri et al.,
2000); (iii) transgenic mice overexpressing IL-1β (Marrache et al.,
2008b).
The overall results from animal studies to date support the
concept that PSCs are activated early in the course of the injury,
most likely due to paracrine effects of factors (cytokines andROS)
produced by injured acinar cells and/or inflammatory cells during
the acute phase of the injury. Activated PSCs are the major source
of collagen in fibrotic areas (confirming findings from in human
studies). As with human chronic pancreatitis, expression of fac-
tors known to activate PSCs are all reported to be upregulated in
experimental pancreatic fibrosis including PDGF and its receptor,
TGFβ and two TGFβ regulated genes SM22α and Cygb/STAP, and
oxidant stress.
Although the above models have provided useful data, caution
needs to be exercised in assessing their direct clinical relevance,
since most have involved relatively non-physiological methods
(e.g., injections of toxin into the pancreatic duct, administration
of supraphysiological levels of caerulein or interventions such as
bile duct ligation), to produce pancreatic damage. However, there
is one rat model produced by chronic alcohol administration and
repeated endotoxin exposure (Vonlaufen et al., 2007a,b) that is
based on a well recognized clinical phenomenon, namely endo-
toxinaemia (secondary to increased gut mucosal permeability)
in alcoholics (Bode et al., 1993; Parlesak, 2005). Thus, the alco-
hol feeding, LPS challenge model possibly represents the most
physiologically relevant model of chronic alcoholic pancreatitis
described to date.
SOURCE OF ACTIVATED PSCs IN THE FIBROTIC PANCREAS –
EVIDENCE FROM ANIMAL MODELS
The significant increase in PSC numbers observed during pancre-
atic injury has raised the question as to whether these increased
numbers are made up largely of resident “pancreatic” PSCs or
whether migratory cells homing to the pancreas from extra-
pancreatic sources such as the bone marrow (in response to
chemotactic signals from the injured organ) also contribute to
the PSC population. Two recent studies have used a gender mis-
match and chimeric approach whereby green fluorescent protein
(GFP) labeled bone marrow derived cells (BMDC) obtained from
GFP transgenic male donor mice were transplanted into lethally
irradiated wild type female rodents (Marrache et al., 2008a,b;
Sparmann et al., 2010). Pancreatic injury was then induced in
recipient mice either by repeated injections of caerulein or using
the chemical toxin dibutyltin chloride (DBTC). Both studies
showed that a small proportion (5–18%) of the proliferative PSCs
in the pancreas could be bone marrow derived, but additional
studies with different models of pancreatic fibrosis need to be
performed to fully characterize the contribution of bone marrow
derived PSCs to progression (or repair) of pancreatic injury.
FATE OF ACTIVATED PSCs AND REVERSAL OF
PANCREATIC FIBROSIS
As the processes of PSC activation are becoming increasingly
clear, the fate of activated PSCs is also attracting increasing
attention. Three possibilities that have been considered include:
(1) reversion to quiescence; (2) apoptosis; and (3) senescence.
Partial reversion to quiescence has been described in vitro upon
exposure to retinol and its metabolites, albumin or culture on
matrigel (a basement membrane like matrix) (McCarroll et al.,
2003b; Kim et al., 2009), however, there is no in vivo evidence
yet to support these findings. On the other hand, apoptosis of
PSCs has been well described in vitro and also recently in vivo
using the alcohol-fed endotoxin challenged model of chronic
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pancreatitis. Vonlaufen et al. (2011) have demonstrated increased
apoptosis of activated PSCs in vivo upon withdrawal of alcohol
in this model. In terms of cell senescence, a very recent paper
by Fitzner and colleagues (2012) has reported that PSCs in long-
term culture (6 weeks) express the senescence marker senescence
associated b-galactosidase (SA-βGal) and are highly susceptible
to immune cell-mediated cytotoxicity. Furthermore, the authors
report that in a rat model of DBTC-induced pancreatitis, PSCs
not only express activation markers, but also senescence markers
leading them to speculate that inflammation, PSC activation and
senescence are timely coupled processes in the injured pancreas.
However, this study did not assess PSC apoptosis. Indeed, the rela-
tive contributions of the processes of apoptosis versus senescence
versus reversion to quiescence in the removal of activated PSCs
after pancreatic injury remain to be clarified.
Regardless of the eventual fate of activated PSCs, advances
in our knowledge of the processes of PSC activation have
helped underpin evidence-based rationales for the development
of potentially useful anti-fibrotic therapies in vivo (albeit only in
experimental models so far). Several treatments/approaches have
been reported to prevent/retard fibrosis in animalmodels, includ-
ing: (i) Antioxidants - vitamin E (the subclass tocotrienol has
been shown to induce PSC death via apoptosis and autophagy)
(Gomez et al., 2004; Vaquero et al., 2007), oxypurinol and allop-
urinol, both xanthine oxidase inhibitors (Pereda et al., 2004; Tasci
et al., 2007), ellagic acid, a plant derived polyphenol with antioxi-
dant, anti-inflammatory and anti-fibrosis activities (Suzuki et al.,
2009), and salvianolic acid, a herbal medicine with free radi-
cal scavenging properties (Lu et al., 2009); (ii) TGFβ suppres-
sion - using TGFβ neutralizing antibodies (Menke et al., 1997),
a herbal medicine Saiko-keishi-to (Su et al., 2001) or a plant
alkaloid halofuginone which inhibits downstream Smad3 phos-
phorylation (Zion et al., 2009); (iii) TNFα inhibition - using a
TNFα antibody (Hughes et al., 1996), soluble TNFα receptors
or an inhibitor of TNFα production pentoxifylline (Pereda et al.,
2004); (iv) anti-inflammatory agents - protease inhibitors such
as camostat mesilate which inhibit proinflammatory cytokine
production by monocytes (Gibo et al., 2005) and the synthetic
carboxamide derivative IS-741 which suppresses macrophage
infiltration into the pancreas, with a consequent decrease in
in vivo PSC activation (Kaku et al., 2007); and (v) modula-
tion of signaling molecules using the PPARγ ligand troglitazone
(Shimizu et al., 2004).
In terms of alcoholic pancreatic fibrosis, withdrawal of alcohol
from the diet after established early pancreatitis, has been shown
to result in complete reversal of pancreatic fibrosis (Vonlaufen
et al., 2011). The authors have attributed this effect to the fact
that the alcohol-induced inhibition of PSC apoptosis (described
earlier) is removed in the absence of alcohol, thereby enabling the
loss of activated PSCs through cell death and interrupting the
fibrogenic process. These observations provide a strong exper-
imental basis for the advocacy of abstinence in patients with
alcoholic pancreatitis in a bid to prevent disease progression.
PSCs IN PANCREATIC CANCER
Pancreatic ductal adenocarcinomas are characterized by an abun-
dant stromal/desmoplastic reaction which, up until recently had
received little attention in terms of its possible role in the patho-
genesis of the disease. It was the emerging evidence of the central
role of PSCs in the fibrosis of chronic pancreatitis that stimulated
researchers to investigate whether the same cells were responsi-
ble for the production of the stroma of pancreatic cancer, and if
so, whether PSCs interacted with cancer cells to influence disease
progression (Apte and Wilson, 2012). Of particular relevance in
this regard were the known increased risk of pancreatic cancer
in patients with chronic pancreatitis (Raimondi et al., 2010) and
the commonalities in gene expression between the stromal com-
partments of chronic pancreatitis and pancreatic cancer (Binkley
et al., 2004).
Histological and immunohistochemical studies of human pan-
creatic cancer sections have shown that activated PSCs are
present in the desmoplastic areas of pancreatic cancer (Apte
et al., 2004). Furthermore, dual staining for activated PSCs
(αSMA) and for collagen mRNA (in situ hybridisation) has estab-
lished that the predominant cells responsible for producing the
fibrosis in pancreatic cancer are PSCs (Figure 5) (Apte et al.,
2004).
The possibility of a close interaction between PSCs and pan-
creatic cancer cells has been examined in vitro (using co-cultures
of PSCs and pancreatic cancer cell lines and/or exposure of
one cell type to conditioned medium from the other) as
well as in vivo (using subcutaneous, orthotopic and trans-
genic mouse models of pancreatic cancer) (Apte and Wilson,
2012).
In vitro STUDIES
Exposure of PSCs to cancer cells (either directly or via condi-
tioned media) results in activation of PSCs (increased prolifer-
ation, ECM synthesis, and migration) (Apte and Wilson, 2012).
In turn, PSCs stimulate cancer cell proliferation but inhibit can-
cer cell apoptosis thereby effectively enhancing the survival of
cancer cells and induce cancer cell migration. The PSC-induced
cancer cell migration is associated with epithelial-mesenchymal
transition in cancer cells as indicated by decreased expression of
epithelial markers such as E-cadherin and increased expression
of mesenchymal markers such as vimentin and Snail in cancer
cells (Kikuta et al., 2010). It is possible that this PSC-induced
epithelial-mesenchymal transition in cancer cells facilitates the
migration of these cells. Recently, a study by Ikenaga et al (Ikenaga
et al., 2010) has reported that a subset of PSCs that overex-
press CD10 (a cell membrane associated MMP) induce cancer
cell invasion and proliferation significantly more than CD10 neg-
ative PSCs, suggesting that functional heterogeneity of PSCs may
influence their effects on tumour progression. Overall, the above
observations suggest that pancreatic cancer cells recruit host PSCs
to their immediate vicinity and that PSCs reciprocate by facilitat-
ing cancer cell growth as well as local invasion (Figure 6). Most
recently, it has been reported that PSCs increase the stem cell phe-
notype of cancer cells, as assessed by increased expression of stem
cell markers such as nestin, ABCG2, and LIN28 in cancer cells
upon co-culture with PSCs (Hamada et al., 2012). These find-
ings have implications for the possible resistance to treatment
of a cancer stem cell niche which then facilitates recurrence of
tumour.
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FIGURE 5 | Dual staining of a human pancreatic cancer section for
α smooth muscle actin (αSMA) and mRNA for collagen. The Figure
depicts low and high power views of a pancreatic cancer section
immunostained for αSMA and for collagen mRNA using in situ hybridisation.
The brown staining for αSMA is co-localized with the blue staining for
collagen mRNA. Importantly, both stains are restricted to the stromal areas
of the section, with no staining of the tumour elements. The findings
indicate that activated PSCs are the predominant source of collagen in the
stroma of pancreatic cancer. Reprinted with permission from Wolters Kluwer
Health.
FIGURE 6 | Bidirectional interactions between pancreatic cancer cells
and PSCs. The diagram outlines the effects of pancreatic cancer cells on
PSCs and vice versa. The observed interaction between these two cell
types facilitates local tumour growth as well as regional and distant
metastasis of pancreatic cancer.
The cancer cell induced increase in ECM synthesis by PSCs
is thought to be mediated by TGFβ1 and fibroblast growth fac-
tor 2 (FGF2), while PSC proliferation is likely mediated by PDGF.
Recent studies have also implicated cycloxygenase 2 (COX-2, the
inducible form of cycloxygenases, enzymes involved in conver-
sion of arachidonic acid to prostaglandin) (Yoshida et al., 2005)
and trefoil factor 1 (TFF1) (Arumugam et al., 2011) (a sta-
ble secretory protein that is upregulated in pancreatic cancer
but not expressed in the normal pancreas) in PSC prolifera-
tion in response to cancer cell secretions. COX-2 is upregu-
lated in PSCs exposed to the pancreatic cancer cell line PANC1
and inhibition of COX-2 prevents PANC1 induced PSC pro-
liferation. ERK1/2 has been identified as the signaling pathway
regulating cancer cell-induced PSC proliferation (Yoshida et al.,
2004).
The possible factors mediating the effects of PSCs on can-
cer cells remain to be characterized. However, PSC-induced
proliferation of cancer cells is thought to be mediated, at least in
part, by PDGF (Xu et al., 2010). Other candidate factors in PSC
secretions that require further study as possible mediators include
the growth factors insulin-like growth factor (IGF), EGF, hep-
atocyte growth factor (HGF), TGFßand other proinflammatory
cytokines.
In vivo STUDIES
In order to obtain in vivo evidence to support the stromal-
tumour interactions observed in vitro, scientists have turned
to murine xenograft or transgenic models. Using an immuno-
compromised mouse model of pancreatic cancer produced by
subcutaneous injection of either a suspension of pancreatic can-
cer cell cells alone or an admixture of cancer cells and PSCs,
Bachem et al. (2005) have shown a significantly increased rate
of tumour growth in the latter group. The larger tumours in
the mice injected with cancer cells + PSCs were due not only
to the expected PSC-mediated fibrosis but also to proliferation
of tumour cells themselves, suggesting that the presence of PSCs
stimulated cancer cell growth.
One of the drawbacks of subcutaneous xenografts is the
absence of the natural tumour microenvironment. Therefore,
orthotopic models which involve injection/implantation of can-
cer cells directly into the organ of interest are a preferred option.
In these models, tumours develop in a relevant anatomical loca-
tion, so that the implanted cancer cells are exposed to the same
microenvironment as may be expected in human cancer. In
addition, orthotopic tumours have the capacity to metastasise
thus allowing studies of tumour progression. Early studies by
Lohr et al. (2001) reported that orthotopic injections of pan-
creatic cancer cells (PANC-1 cell line) transfected with TGFβ1
cDNA resulted in the induction of an extensive stromal reaction
around the pancreatic tumour. Although not specifically stud-
ied at the time, this stromal reaction was most likely via the
TGFβ-induced activation of stromal cells/fibroblasts/ in the host
(mouse) pancreas.
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More recently, orthotopic models of pancreatic cancer
have been described wherein human pancreatic cancer cells
(MiaPaCa-2, AsPC-1) with or without human pancreatic stel-
late cells (hPSCs) were injected directly into the mouse pancreas
(Vonlaufen et al., 2008; Xu et al., 2010). In the presence of
hPSCs, local tumour growth, and importantly, regional and dis-
tant metastasis were significantly enhanced. Tumours produced
by the mixture of cancer cells and PSCs exhibited bands of fibro-
sis (resembling desmoplasia) and the presence of αSMA positive
activated PSCs as well as increased proliferation and decreased
apoptosis of cancer cells. These data concur well with the interac-
tions between PSCs and cancer cells observed in vitro and strongly
support an active role for PSCs in cancer progression (increased
local growth and distant metastasis).
Neo-angiogenesis is a well recognized event in malignant
tumours and is thought to be a major factor influencing can-
cer metastasis. PSCs significantly enhance tumour angiogenesis
as indicated by upregulation of the endothelial cell marker CD31
in orthotopic tumours produced by cancer cell+ PSCs compared
to tumours produced by injection of cancer cells alone (Xu et al.,
2010). These in vivo findings are supported by in vitro observa-
tions that PSCs stimulate tube formation of human microvas-
cular endothelial cells, an effect that is mediated by vascular
endothelial growth factor (VEGF) secreted by PSCs (Xu et al.,
2010).
The process of angiogenesis in human pancreatic cancers
may be somewhat more complex than that in mouse models.
Studies with human pancreatic cancer sections indicate that neo-
angiogenesis is limited to the invading front of the tumour while
the central areas of the tumour have few patent blood vessels
and are relatively hypoxic (Erkan et al., 2009). In an attempt
to address this issue, Erkan et al. (2009) assessed the effects of
hypoxia on the interactions of PSCs with endothelial cells. Using
co-cultures of the two cell types, they found that the VEGF-
mediated proliferative effect of PSCs on endothelial cells observed
under normoxic conditions were dampened under hypoxic con-
ditions. At the same time however, hypoxia significantly increased
PSC activation and ECM synthesis. Further studies are needed to
clarify the relative importance of new blood vessel formation ver-
sus tumour hypoxia in terms of the influence of PSCs on cancer
behavior.
One of the intriguing features of PSC biology reported
recently, is the ability of the cells migrate through an endothe-
lial layer in vitro, suggesting that PSCs have the capacity to
intravasate/extravasate to and from blood vessels in vivo (Xu
et al., 2010). In the presence of cancer cells transendothelial
migration of PSCs is further stimulated, an effect which may be
mediated by PDGF in cancer cell secretions (Xu et al., 2010).
More interestingly, it has now been shown, using a gender mis-
match approach, that PSCs from the primary tumour (produced
by implantation of female pancreatic cancer cells + male PSCs
into the pancreas of female mice) can be detected in distant
metastatic sites as y chromosome positive cells using fluorescent
in situ hybridization. These findings suggest that PSCs can travel
to distant metastatic sites (possibly with cancer cells) where they
likely facilitate the seeding, survival, and growth of cancer cells.
Indeed, similar observations have now been reported in a model
of lung cancer (Duda et al., 2010). These findings challenge the
long held concept that metastasis is the sole preserve of cancer
cells.
The above studies provide convincing evidence of an active
role of PSCs in pancreatic cancer progression. It is now also
acknowledged that PSCs (via the production of dense stroma)
may play a role in the well documented resistance of pancre-
atic cancer to chemotherapy and radiotherapy (Hanahan and
Weinberg, 2011). In this regard, Olive et al. (2009) have shown
in an orthotopic model of pancreatic cancer, that gemcitabine
(a widely used chemotherapeutic agent for pancreatic cancer)
is sequestered in the stromal area of pancreatic cancer, thereby
limiting the availability of drug to cancer cells and providing a
possible explanation for the chemoresistance of the disease. In
addition, Mantoni and colleagues (2011) have reported that PSCs
protect cancer cells from radiation via a ß1-integrin dependent
pathway.
Given the accumulating evidence of the influence of PSCs
on pancreatic cancer behavior, it is logical that the stroma
is now seen as an important alternative therapeutic target to
improve the outcome of this disease. Several recent studies
have reported encouraging findings with such approaches in
pre-clinical models. In a transgenic mouse model of pancre-
atic cancer, Olive et al. (2009) have shown that inhibition of
the Sonic hedgehog pathway in PSCs (achieved by using vita-
min A containing liposomes to specifically target stellate cells)
transiently decreased PSC activation resulting in stromal deple-
tion and increased accumulation of gemcitabine in cancer cells
leading to cancer cell destruction. Von Hoff et al. (2011) have
observed stromal depletion upon treatment of subcutaneous
xenografts in mice with nanoparticle albumin bound paclitaxel,
while Froeling and colleagues (2011) have reported decreased
tumour growth in a transgenic mouse model of pancreatic can-
cer treated with the PSC inhibitor all trans retinoic acid (ATRA).
It is anticipated that ongoing research will also target the sig-
naling pathways/molecules that mediate PSC-cancer cell interac-
tions so as to inhibit the facilitatory effects of PSCs on cancer
progression.
To conclude, over the past two decades there has been
a steep rise in our understanding of pancreatic fibrogenesis
and the central role of PSCs in this process. It is also clear
that PSCs have functions over and beyond the regulation of
pathologic fibrosis in the pancreas, with the cells likely play-
ing important roles in health as immune and/or progenitor
cells and as intermediary cells in digestive enzyme secretion
(at least in humans). Improved understanding of PSC biol-
ogy will underpin the development of novel therapies in the
future for the treatment of chronic pancreatitis and pancreatic
cancer.
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